IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences (NASDAQ: IDYA) has announced the granting of non-qualified stock options to four newly hired employees through its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved options to purchase 185,400 shares of common stock at an exercise price of $19.07 per share, matching the closing price on the Nasdaq Global Select Market on the grant date.
The stock options, granted under Nasdaq Listing Rule 5635(c)(4), feature a 10-year term with a four-year vesting schedule: 25% vesting after the first year, followed by monthly installments over three years. These inducement grants are specifically designed for new employees who were not previously with IDEAYA, contingent upon their continued service with the company.
IDEAYA Biosciences (NASDAQ: IDYA) ha annunciato la concessione di opzioni su azioni non qualificate a quattro nuovi dipendenti nell'ambito del suo Piano Incentivi per l'Assunzione 2023. Il Comitato per la Retribuzione ha approvato opzioni per l'acquisto di 185.400 azioni ordinarie a un prezzo di esercizio di 19,07 $ per azione, corrispondente al prezzo di chiusura sul Nasdaq Global Select Market nella data di concessione.
Le opzioni su azioni, concesse secondo la Regola Nasdaq 5635(c)(4), hanno una durata di 10 anni e un piano di maturazione quadriennale: il 25% matura dopo il primo anno, seguito da rate mensili per i successivi tre anni. Questi incentivi sono specificamente pensati per i nuovi dipendenti che non erano precedentemente impiegati da IDEAYA, subordinati alla loro permanenza in azienda.
IDEAYA Biosciences (NASDAQ: IDYA) ha anunciado la concesión de opciones sobre acciones no calificadas a cuatro empleados recientemente contratados a través de su Plan de Incentivos de Empleo 2023. El Comité de Compensación aprobó opciones para comprar 185,400 acciones comunes a un precio de ejercicio de $19.07 por acción, igualando el precio de cierre en el Nasdaq Global Select Market en la fecha de concesión.
Las opciones sobre acciones, otorgadas bajo la Regla 5635(c)(4) del Nasdaq, tienen un plazo de 10 años con un calendario de adquisición de derechos de cuatro años: 25% se adquiere después del primer año, seguido de pagos mensuales durante los siguientes tres años. Estas concesiones de incentivo están diseñadas específicamente para nuevos empleados que no formaban parte de IDEAYA anteriormente, condicionadas a su permanencia en la empresa.
IDEAYA Biosciences (NASDAQ: IDYA)는 2023년 고용 유인 인센티브 계획을 통해 새로 채용된 네 명의 직원에게 비자격 주식 옵션을 부여했다고 발표했습니다. 보상 위원회는 부여일 나스닥 글로벌 셀렉트 마켓 종가에 맞춰 185,400주의 보통주를 주당 19.07달러에 매수할 수 있는 옵션을 승인했습니다.
나스닥 상장 규칙 5635(c)(4)에 따라 부여된 이 주식 옵션은 10년 만기이며 4년간 권리 취득 일정이 적용됩니다: 첫 해 후 25%가 취득되고 이후 3년간 매월 분할 취득됩니다. 이 인센티브 부여는 이전에 IDEAYA에 근무하지 않았던 신규 직원들을 위해 특별히 설계되었으며, 회사에 계속 근무하는 조건입니다.
IDEAYA Biosciences (NASDAQ : IDYA) a annoncé l’attribution d’options d’achat d’actions non qualifiées à quatre nouveaux employés dans le cadre de son Plan d’Incitation à l’Embauche 2023. Le comité de rémunération a approuvé des options portant sur l’achat de 185 400 actions ordinaires au prix d’exercice de 19,07 $ par action, correspondant au cours de clôture sur le Nasdaq Global Select Market à la date d’attribution.
Les options d’achat d’actions, accordées conformément à la règle Nasdaq 5635(c)(4), ont une durée de 10 ans avec un calendrier d’acquisition des droits sur quatre ans : 25 % acquis après la première année, puis des versements mensuels sur les trois années suivantes. Ces attributions d’incitation sont spécifiquement destinées aux nouveaux employés qui n’étaient pas auparavant chez IDEAYA, sous réserve de leur maintien dans l’entreprise.
IDEAYA Biosciences (NASDAQ: IDYA) hat die Gewährung von nicht qualifizierten Aktienoptionen an vier neu eingestellte Mitarbeiter im Rahmen seines Anreizplans für Neueinstellungen 2023 angekündigt. Der Vergütungsausschuss genehmigte Optionen zum Kauf von 185.400 Aktien zum Ausübungspreis von 19,07 $ pro Aktie, entsprechend dem Schlusskurs am Nasdaq Global Select Market am Gewährungstag.
Die Aktienoptionen, die gemäß Nasdaq-Listing-Regel 5635(c)(4) gewährt wurden, haben eine Laufzeit von 10 Jahren mit einem vierjährigen Vesting-Zeitplan: 25 % werden nach dem ersten Jahr fällig, gefolgt von monatlichen Raten über die nächsten drei Jahre. Diese Anreizgewährungen sind speziell für neue Mitarbeiter gedacht, die zuvor nicht bei IDEAYA beschäftigt waren, und setzen deren fortgesetzte Beschäftigung im Unternehmen voraus.
- Company demonstrates ability to attract new talent with equity compensation
- Stock options are priced at market value, aligning with shareholder interests
- Potential future dilution from 185,400 new stock options
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Chief Accounting Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302438045.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What is the vesting schedule for IDYA's newly granted stock options?
How many shares of IDYA stock were granted in the inducement awards?
What is the exercise price for IDYA's newly issued stock options?
How long is the term of IDYA's newly granted stock options?
